Massmutual Trust Co. FSB ADV Has $39,000 Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Massmutual Trust Co. FSB ADV lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 86.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 284 shares of the life sciences company’s stock after purchasing an additional 132 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Illumina were worth $39,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Vanguard Group Inc. boosted its position in Illumina by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 18,178,513 shares of the life sciences company’s stock worth $2,531,176,000 after acquiring an additional 210,755 shares during the last quarter. Edgewood Management LLC boosted its position in Illumina by 4.6% during the 4th quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock worth $957,762,000 after acquiring an additional 302,222 shares during the last quarter. Capital World Investors acquired a new position in Illumina during the 4th quarter worth approximately $271,753,000. Norges Bank acquired a new position in Illumina during the 4th quarter worth approximately $264,636,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Illumina by 4.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 925,198 shares of the life sciences company’s stock worth $128,825,000 after acquiring an additional 41,298 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent research reports. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Tuesday, May 7th. Evercore ISI dropped their price objective on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 11th. Jefferies Financial Group started coverage on Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective on the stock. Barclays upped their price objective on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Finally, OTR Global reiterated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $158.14.

Illumina Stock Performance

ILMN stock opened at $108.57 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The business’s fifty day moving average price is $112.71 and its two-hundred day moving average price is $127.62. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $202.85.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.08 EPS. As a group, analysts anticipate that Illumina, Inc. will post 1.04 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.